• Viral infections

Combivir Generic Name & Formulations

General Description

Lamivudine 150mg, zidovudine 300mg; scored tabs.

Pharmacological Class

Nucleoside analogues (reverse transcriptase inhibitors).

How Supplied



Combivir Indications


HIV-1 infection, in combination with other antiretroviral agents.

Combivir Dosage and Administration

Adults and Children

<30kg: not recommended. ≥30kg: 1 tab twice daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended; use individual components.

Combivir Contraindications

Not Applicable

Combivir Boxed Warnings

Boxed Warning

Hematologic toxicity. Myopathy. Lactic acidosis and severe hepatomegaly with steatosis. Exacerbations of hepatitis B.

Combivir Warnings/Precautions


Risk of hematologic toxicity/bone marrow suppression; monitor CBCs esp. in advanced HIV-1 disease; interrupt dose if anemia or neutropenia occurs. Myopathy with prolonged zidovudine use. Suspend if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Not for treating chronic HBV infection; closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. History of pancreatitis. Monitor for lipoatrophy; use alternatives if suspected. Women. Obesity. Elderly. Pregnancy. Nursing mothers: not recommended.

Combivir Pharmacokinetics

See Literature

Combivir Interactions


Avoid concomitant stavudine, doxorubicin, nucleoside analogues (eg, ribavirin), sorbitol-containing products. Increased hematologic toxicity with ganciclovir, interferon alpha, ribavirin, other bone marrow suppressants or cytotoxic drugs. Monitor for treatment-associated toxicities (eg, hepatic decompensation) with interferon-alpha with or without ribavirin.

Combivir Adverse Reactions

Adverse Reactions

Headache, nausea, malaise, fatigue, nasal symptoms, diarrhea, cough; neutropenia, anemia, lactic acidosis, severe hepatomegaly with steatosis, myopathy, myositis, immune reconstitution syndrome, pancreatitis (discontinue if occurs), lipoatrophy.

Combivir Clinical Trials

See Literature

Combivir Note


Register pregnant patients exposed to lamivudine by calling (800) 258-4263.

Combivir Patient Counseling

See Literature